Free Trial

Wall Street Zen Downgrades Sanuwave Health (NASDAQ:SNWV) to Hold

Sanuwave Health logo with Medical background

Key Points

  • Analysts at Wall Street Zen have downgraded Sanuwave Health's stock from a "buy" to a "hold" rating.
  • Sanuwave Health reported a quarterly earnings beat, with $0.01 earnings per share, surpassing estimates of ($0.09).
  • The company's current market cap stands at $298.92 million, with shares trading at $34.88 after reaching a high of $46.58 in the past year.
  • Interested in Sanuwave Health? Here are five stocks we like better.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

A number of other research firms have also recently issued reports on SNWV. Northland Securities started coverage on Sanuwave Health in a report on Wednesday, September 3rd. They issued an "outperform" rating and a $55.00 price target for the company. Northland Capmk raised Sanuwave Health to a "strong-buy" rating in a report on Wednesday, September 3rd. Finally, Roth Capital boosted their price objective on Sanuwave Health from $54.00 to $55.00 and gave the stock a "buy" rating in a report on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $55.00.

View Our Latest Stock Analysis on Sanuwave Health

Sanuwave Health Price Performance

Shares of NASDAQ:SNWV traded down $0.09 during trading on Friday, reaching $34.79. The stock had a trading volume of 22,397 shares, compared to its average volume of 50,852. Sanuwave Health has a 52 week low of $5.63 and a 52 week high of $46.58. The stock has a market capitalization of $298.15 million, a price-to-earnings ratio of -4.22 and a beta of 1.39. The firm's fifty day moving average is $37.89.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.10. The business had revenue of $10.16 million during the quarter, compared to the consensus estimate of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Institutional Trading of Sanuwave Health

Several hedge funds have recently made changes to their positions in the company. Legal & General Group Plc bought a new position in Sanuwave Health in the 2nd quarter worth about $26,000. BNP Paribas Financial Markets purchased a new position in shares of Sanuwave Health in the 2nd quarter worth about $46,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Sanuwave Health in the 1st quarter worth about $47,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Sanuwave Health in the 2nd quarter worth about $52,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Sanuwave Health in the 2nd quarter worth about $102,000. 42.53% of the stock is currently owned by institutional investors.

Sanuwave Health Company Profile

(Get Free Report)

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

Further Reading

Should You Invest $1,000 in Sanuwave Health Right Now?

Before you consider Sanuwave Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanuwave Health wasn't on the list.

While Sanuwave Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.